Mr Matthew Fisher

BSc (Hons)

School of Medicine and Population Health

Technical Specialist – BSU

matthew.fisher@sheffield.ac.uk
+44 114 215 9067

GU36, The Medical School

Full contact details

Mr Matthew Fisher
School of Medicine and Population Health
GU36
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Research interests: The TMG study the blood vessels that supply tumours with oxygen and nutrients and their role in cancer therapy. Tumours require a blood supply to grow and the blood vessels provide a route for the spread of tumour cells to other sites in the body. Therefore, targeting treatment to the blood vessels rather than the tumour cells is a potential means of killing tumours. Much of the research involves using vascular disrupting agents (VDAs) e.g. CA4P, and the susceptibility of tumour vessels to vascular shutdown.

Publications

Show: Featured publications All publications

Featured publications

This person does not have any publications available.

All publications

Journal articles

Al-janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, de Bono J, Nunns H, Bailey C , Junker-Jensen A et al (2024) Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Journal for ImmunoTherapy of Cancer, 12(7). View this article in WRRO
Hodgson K, Orozco-Moreno M, Goode EA, Fisher M, Garnham R, Beatson R, Turner H, Livermore K, Zhou Y, Wilson L , Visser EA et al (2024) Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone. eBioMedicine, 104. View this article in WRRO
Mironov A, Fisher M, Narayanan P, Elsayed R, Karabulutoglu M & Akhtar N (2023) Rac1 controls cell turnover and reversibility of the involution process in postpartum mammary glands. PLoS Biology, 21(1).
Brown AW, Holmes T, Fisher M, Tozer GM, Harrity JPA & Kanthou C (2018) Cover feature : Evaluation of sydnone-based analogues of Combretastatin A-4 phosphate (CA4P) as vascular disrupting agents for use in cancer therapy (ChemMedChem 24/2018). ChemMedChem, 13(24), 2600-2600. View this article in WRRO
Harrity JPA, Brown A, Holmes T, Fisher M, Tozer G & Kanthou C (2018) Evaluation of sydnone-based analogs of combretastatin A-4 phosphate (CA4P) as vascular disrupting agents for use in cancer therapy. ChemMedChem, 13(24), 2618-2626. View this article in WRRO
Lath DL, Buckle CH, Evans HR, Fisher M, Down JM, Lawson MA & Chantry AD (2018) ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo. PLoS One, 13(6). View this article in WRRO
Byers RA, Fisher M, Brown NJ, Tozer GM & Matcher SJ (2017) Vascular patterning of subcutaneous mouse fibrosarcomas expressing individual VEGF isoforms can be differentiated using angiographic optical coherence tomography. Biomedical Optics Express, 8(10), 4551-4567. View this article in WRRO
Shepherd J, Fisher M, Welford A, McDonald D, Kanthou C & Tozer G (2017) The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate. Oncotarget, 2017(8), 95648-95661. View this article in WRRO
English WR, Lunt SJ, Fisher M, Lefley DV, Dhingra M, Lee Y-C, Bingham K, Hurrell JE, Lyons SK, Kanthou C & Tozer GM (2017) Differential Expression of VEGFA Isoforms Regulates Metastasis and Response to Anti-VEGFA Therapy in Sarcoma. Cancer Research, 77(10). View this article in WRRO
Brown AW, Fisher M, Tozer GM, Kanthou C & Harrity JP (2016) Sydnone Cycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4.. Journal of Medicinal Chemistry, 59(20), 9473-9488. View this article in WRRO
Williams LJ, Mukherjee D, Fisher M, Reyes-Aldasoro CC, Akerman S, Kanthou C & Tozer GM (2014) An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate. British Journal of Pharmacology, 171(21), 4902-4913. View this article in WRRO
Akerman S, Fisher M, Daniel RA, Lefley D, Reyes-Aldasoro CC, Lunt SJ, Harris S, Bjorndahl M, Williams LJ, Evans H , Barber PR et al (2013) Influence of soluble or matrix-bound isoforms of vascular endothelial growth factor-A on tumor response to vascular-targeted strategies. International Journal of Cancer, n/a-n/a.
Harris S, Craze M, Newton J, Fisher M, Shima DT, Tozer GM & Kanthou C (2012) Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale. PLoS ONE, 7(5). View this article in WRRO
Lunt SJ, Lefley DV, Fisher M, Daniel R, Kanthou C & Tozer G (2012) Abstract 5296: The role of VEGF receptors 1 and 2 on tumor vascularization and progression in single VEGF isoform expressing tumors. Cancer Research, 72(8_Supplement), 5296-5296.
Harris S, Evans C, Burley E, Fisher M, Greaves CL, Kanthou C & Tozer GM (2012) Abstract 1371: Delineating the function of single VEGF isoforms using both proteomic and molecular approaches. Cancer Research, 72(8_Supplement), 1371-1371.
Daniel RA, Fisher M, Flores-Merino MV, Battaglia G, Ryan AJ, Blakey DC & Tozer GM (2011) Abstract 3279: Effects of the isoforms of the angiogenic growth factor VEGF on neo-vascularization and tumor response to the tyrosine kinase inhibitor cediranib. Cancer Research, 71(8_Supplement), 3279-3279.
Abigail WF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Serio CD, Naldini L, De Palma M, Tozer GM & Lewis CE (2011) Abstract 2849: Tie2-expressing macrophages (TEM) depletion may enhance the clinical efficacy of combretastatin A-4-phosphate (CA-4-P). Cancer Research, 71(8_Supplement), 2849-2849.
Jane Lunt S, Akerman S, Hill SA, Fisher M, Wright VJ, Reyes‐Aldasoro CC, Tozer GM & Kanthou C (2011) Vascular effects dominate solid tumor response to treatment with combretastatin A‐4‐phosphate. International Journal of Cancer, 129(8), 1979-1989.
Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Di Serio C, Naldini L, De Palma M, Tozer GM & Lewis CE (2011) TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. Journal of Clinical Investigation, 121(5), 1969-1973.
Akerman S, Reyes-Aldasoro CC, Fisher M, Pettyjohn KL, Bjorndahl MA, Evans H & Tozer GM (2011) Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to vascular targeting agents. Medical Engineering and Physics, 33(7), 805-809. View this article in WRRO
Akerman S, Reyes-Aldasoro CC, Fisher M, Pettyjohn KL, Björndahl MA, Evans H & Tozer GM (2010) Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to vascular targeting agents. Medical Engineering and Physics.

Conference proceedings papers

Valluru MK, Mukherjee D, Fisher M, Madrigal-Esquivel C, Bradford J, Kanthou C, Tozer GM & English WR (2019) VEGFA isoform switching in soft tissue sarcoma is associated with decreased survival. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 100(4) (pp A41-A41)
Lee YC, Claeyssens F, Fisher M, Lefley DV, Kanthou C, Tozer GM & English WR (2019) Differences in VEGFA isoform expression regulate modes of migration and their sensitivity to anti-VEGFA therapy. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 100(4) (pp A25-A25)
English WR, Lunt SJ, Fisher M, Hurrell JE, Lefley DV, Mukherjee D, Daniel R, Lyons SK, Kanthou C & Tozer GM (2015) Abstract A57: Differential tumor cell expression of VEGF isoforms impacts on the tumor microenvironment, metastasis and radiation response in a mouse fibrosarcoma model. Cancer Research, Vol. 75(1_Supplement) (pp A57-A57)
Williams L, Fisher M, Reyes-Aldasoro CC, Kanthou C & Tozer GM (2011) Abstract 1578: A critical role for RhoA-GTPase signaling in the tumor vascular disrupting action of combretastatin-A4-phosphate in vivo. Cancer Research, Vol. 71(8_Supplement) (pp 1578-1578)

Preprints

Al-janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, De Bono J, Nunns H, Bailey C , Juncker-Jensen A et al (2024) Targeting of a STING Agonist to Perivascular Macrophages in Prostate Tumors Delays Resistance to Androgen Deprivation Therapy, Cold Spring Harbor Laboratory.
Mironov A, Fisher M, Elsayed R, Karabulutoglu M & Akhtar N (2022) Rac1 controls cell turnover and mammary gland reversibility in post-partum involution, Cold Spring Harbor Laboratory.